155 related articles for article (PubMed ID: 37103079)
101. Association of Survival With Immune-Related Adverse Events-Time to Consider the Duration of Treatment-Reply.
Du Y; Da M; Wang F
JAMA Dermatol; 2024 Mar; 160(3):369-370. PubMed ID: 38265783
[No Abstract] [Full Text] [Related]
102. Geriatric nutritional risk index as a predictor of prognosis in hematologic malignancies: a systematic review and meta-analysis.
Yu Q; Tian M; Pi G; Jia Y; Jin X
Front Nutr; 2023; 10():1274592. PubMed ID: 37941772
[TBL] [Abstract][Full Text] [Related]
103. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Rev Anticancer Ther; 2022 Jun; 22(6):583-595. PubMed ID: 35472312
[TBL] [Abstract][Full Text] [Related]
104. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
105. Influence of Geriatric Nutritional Risk Index on Occurrence of Adverse Events and Duration of Treatment in Patients With Lymphoma Receiving R-CHOP Therapy.
Kikuchi K; Sawada M; Takeda G; Watanabe T; Souma T; Sato H
In Vivo; 2023; 37(3):1297-1303. PubMed ID: 37103079
[TBL] [Abstract][Full Text] [Related]
106. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
107. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
108. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
109. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
110. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
111. Prognostic values of geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI) in elderly patients with Diffuse Large B-Cell Lymphoma.
Yan D; Shen Z; Zhang S; Hu L; Sun Q; Xu K; Jin Y; Sang W
J Cancer; 2021; 12(23):7010-7017. PubMed ID: 34729103
[No Abstract] [Full Text] [Related]
112. Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study.
Chuang TM; Liu YC; Hsiao HH; Wang HC; Du JS; Yeh TJ; Gau YC; Ke YL; Yang CI; Lee CP; Hsu CM; Cho SF
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579119
[TBL] [Abstract][Full Text] [Related]
113. ESPEN practical guideline: Clinical Nutrition in cancer.
Muscaritoli M; Arends J; Bachmann P; Baracos V; Barthelemy N; Bertz H; Bozzetti F; Hütterer E; Isenring E; Kaasa S; Krznaric Z; Laird B; Larsson M; Laviano A; Mühlebach S; Oldervoll L; Ravasco P; Solheim TS; Strasser F; de van der Schueren M; Preiser JC; Bischoff SC
Clin Nutr; 2021 May; 40(5):2898-2913. PubMed ID: 33946039
[TBL] [Abstract][Full Text] [Related]
114. The Geriatric Nutritional Risk Index as a Prognostic Factor in Patients with Advanced Non-Small-Cell Lung Cancer.
Peng SM; Yu N; Ren JJ; Xu JY; Chen GC; Yang JR; Li ZN; Du HZ; Li DP; Zhang YS; Qin LQ
Nutr Cancer; 2021; 73(11-12):2832-2841. PubMed ID: 33356605
[TBL] [Abstract][Full Text] [Related]
115. The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper.
Evans DC; Corkins MR; Malone A; Miller S; Mogensen KM; Guenter P; Jensen GL;
Nutr Clin Pract; 2021 Feb; 36(1):22-28. PubMed ID: 33125793
[TBL] [Abstract][Full Text] [Related]
116. Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma.
Matsukawa T; Suto K; Kanaya M; Izumiyama K; Minauchi K; Yoshida S; Oda H; Miyagishima T; Mori A; Ota S; Hashimoto D; Teshima T;
Ann Hematol; 2020 Dec; 99(12):2859-2868. PubMed ID: 32970194
[TBL] [Abstract][Full Text] [Related]
117.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
118.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
119.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
